PL3982956T3 - Potrójna kompozycja farmaceutyczna na zakażenie białkowe - Google Patents
Potrójna kompozycja farmaceutyczna na zakażenie białkoweInfo
- Publication number
- PL3982956T3 PL3982956T3 PL20823121.7T PL20823121T PL3982956T3 PL 3982956 T3 PL3982956 T3 PL 3982956T3 PL 20823121 T PL20823121 T PL 20823121T PL 3982956 T3 PL3982956 T3 PL 3982956T3
- Authority
- PL
- Poland
- Prior art keywords
- proteinaceous
- infection
- pharmaceutical composition
- triple
- triple pharmaceutical
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/65—Tetracyclines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Immunology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Transplantation (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962861855P | 2019-06-14 | 2019-06-14 | |
| US16/504,723 US20200000829A1 (en) | 2018-06-27 | 2019-07-08 | Therapy and prevention of prion protein complex infections |
| US16/565,242 US10729705B2 (en) | 2018-06-27 | 2019-09-09 | Therapy and prevention of prion protein complex infections in non-human animals |
| PCT/US2020/037787 WO2020252475A1 (en) | 2019-06-14 | 2020-06-15 | Triple pharmaceutical composition for proteinaceous infection |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PL3982956T3 true PL3982956T3 (pl) | 2024-10-28 |
Family
ID=73782140
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL20823121.7T PL3982956T3 (pl) | 2019-06-14 | 2020-06-15 | Potrójna kompozycja farmaceutyczna na zakażenie białkowe |
Country Status (21)
| Country | Link |
|---|---|
| EP (1) | EP3982956B1 (pl) |
| JP (1) | JP7645201B2 (pl) |
| KR (2) | KR20250161037A (pl) |
| CN (2) | CN120771163A (pl) |
| BR (1) | BR112021025253A2 (pl) |
| CA (1) | CA3142164A1 (pl) |
| DK (1) | DK3982956T3 (pl) |
| ES (1) | ES2984684T3 (pl) |
| FI (1) | FI3982956T3 (pl) |
| HR (1) | HRP20241019T1 (pl) |
| HU (1) | HUE068048T2 (pl) |
| LT (1) | LT3982956T (pl) |
| MX (1) | MX2021015266A (pl) |
| MY (1) | MY210598A (pl) |
| PL (1) | PL3982956T3 (pl) |
| PT (1) | PT3982956T (pl) |
| RS (1) | RS65836B1 (pl) |
| SG (1) | SG11202113265PA (pl) |
| SI (1) | SI3982956T1 (pl) |
| SM (1) | SMT202400304T1 (pl) |
| WO (1) | WO2020252475A1 (pl) |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7189703B2 (en) * | 1998-01-09 | 2007-03-13 | Intracell, Llc | Treatment and diagnosis of alzheimer's disease |
| NZ538198A (en) * | 2002-07-12 | 2006-11-30 | Univ New York State Res Found | Method for reducing C-reactive protein (CRP) levels by administering a non-antibacterial tetracycline formulation or a low dose of an antibacterial tetracycline formulation |
| KR100538780B1 (ko) * | 2002-09-10 | 2005-12-23 | 주식회사 브레인트로피아 | 미노사이클린을 유효성분으로 함유하는 치매 및 기억력감퇴의 예방 및 치료용 조성물 |
| US20040127471A1 (en) * | 2002-09-17 | 2004-07-01 | Barry Reisberg | Methods of treating age associated memory impairment (AAMI), mild cognitive impairment (MCI), and dementias with cell cycle inhibitors |
| US20050271717A1 (en) * | 2003-06-12 | 2005-12-08 | Alfred Berchielli | Pharmaceutical compositions of atorvastatin |
| JP2007532624A (ja) * | 2004-04-14 | 2007-11-15 | ワーナー−ランバート カンパニー リミテッド ライアビリティー カンパニー | アルツハイマー病の治療のための療法組合せ |
| WO2013061161A2 (en) * | 2011-10-28 | 2013-05-02 | Green Bcn Consulting Services Sl | New combination therapies for treating neurological disorders |
| US20140271923A1 (en) * | 2013-03-14 | 2014-09-18 | Christopher Brian Reid | Compositions & formulations for preventing and treating chronic diseases that cluster in patients such as cardiovascular disease, diabetes, obesity, polycystic ovary syndrome, hyperlipidemia and hypertension, as well as for preventing and treating other diseases and conditions |
| EA201700052A1 (ru) * | 2014-08-18 | 2017-06-30 | Фабризио Де Силвестри | Применение в одной пилюле, таблетке, капсуле миноциклина, ациклогуанозина, аторвастатина и витамина d для лечения ревматоидного артрита |
| DE102016208567A1 (de) * | 2016-05-19 | 2017-11-23 | Heraeus Medical Gmbh | Polymerlösung zur Viscosupplementation |
| WO2018108991A2 (en) * | 2016-12-13 | 2018-06-21 | Ecole Polytechnique Federale De Lausanne | Methods of treating amyloid-beta peptide diseases |
| US10350226B1 (en) * | 2018-06-27 | 2019-07-16 | Joshua O. Atiba | Therapy and prevention of prion protein complex infections |
-
2020
- 2020-06-15 PL PL20823121.7T patent/PL3982956T3/pl unknown
- 2020-06-15 CN CN202511147531.8A patent/CN120771163A/zh active Pending
- 2020-06-15 KR KR1020257035846A patent/KR20250161037A/ko active Pending
- 2020-06-15 PT PT208231217T patent/PT3982956T/pt unknown
- 2020-06-15 FI FIEP20823121.7T patent/FI3982956T3/fi active
- 2020-06-15 BR BR112021025253A patent/BR112021025253A2/pt unknown
- 2020-06-15 CA CA3142164A patent/CA3142164A1/en active Pending
- 2020-06-15 CN CN202080042131.XA patent/CN114007609A/zh active Pending
- 2020-06-15 RS RS20240852A patent/RS65836B1/sr unknown
- 2020-06-15 MX MX2021015266A patent/MX2021015266A/es unknown
- 2020-06-15 HU HUE20823121A patent/HUE068048T2/hu unknown
- 2020-06-15 SM SM20240304T patent/SMT202400304T1/it unknown
- 2020-06-15 LT LTEPPCT/US2020/037787T patent/LT3982956T/lt unknown
- 2020-06-15 DK DK20823121.7T patent/DK3982956T3/da active
- 2020-06-15 HR HRP20241019TT patent/HRP20241019T1/hr unknown
- 2020-06-15 SI SI202030464T patent/SI3982956T1/sl unknown
- 2020-06-15 MY MYPI2021007329A patent/MY210598A/en unknown
- 2020-06-15 KR KR1020217041835A patent/KR102878748B1/ko active Active
- 2020-06-15 EP EP20823121.7A patent/EP3982956B1/en active Active
- 2020-06-15 ES ES20823121T patent/ES2984684T3/es active Active
- 2020-06-15 JP JP2021573291A patent/JP7645201B2/ja active Active
- 2020-06-15 SG SG11202113265PA patent/SG11202113265PA/en unknown
- 2020-06-15 WO PCT/US2020/037787 patent/WO2020252475A1/en not_active Ceased
Also Published As
| Publication number | Publication date |
|---|---|
| CA3142164A1 (en) | 2020-12-17 |
| MY210598A (en) | 2025-10-01 |
| RS65836B1 (sr) | 2024-09-30 |
| JP2022537132A (ja) | 2022-08-24 |
| KR102878748B1 (ko) | 2025-10-29 |
| SI3982956T1 (sl) | 2024-09-30 |
| KR20250161037A (ko) | 2025-11-14 |
| CN120771163A (zh) | 2025-10-14 |
| EP3982956A1 (en) | 2022-04-20 |
| SMT202400304T1 (it) | 2024-11-15 |
| BR112021025253A2 (pt) | 2022-04-12 |
| DK3982956T3 (da) | 2024-07-22 |
| LT3982956T (lt) | 2024-08-26 |
| MX2021015266A (es) | 2022-01-18 |
| KR20220020832A (ko) | 2022-02-21 |
| PT3982956T (pt) | 2024-07-26 |
| JP7645201B2 (ja) | 2025-03-13 |
| EP3982956B1 (en) | 2024-06-12 |
| SG11202113265PA (en) | 2021-12-30 |
| EP3982956A4 (en) | 2023-05-03 |
| WO2020252475A1 (en) | 2020-12-17 |
| FI3982956T3 (fi) | 2024-08-06 |
| CN114007609A (zh) | 2022-02-01 |
| ES2984684T3 (es) | 2024-10-30 |
| HRP20241019T1 (hr) | 2024-11-08 |
| HUE068048T2 (hu) | 2024-12-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| GB202019241D0 (en) | Pharmaceutical composition | |
| GB201911517D0 (en) | Pharmaceutical composition | |
| IL290469A (en) | Oral pharmaceutical preparation | |
| HUE064916T2 (hu) | Gyógyászati készítmény | |
| IL285728A (en) | Pharmaceutical composition | |
| AU2020356348B2 (en) | Pharmaceutical compounds | |
| PL3949952T3 (pl) | Kompozycja farmaceutyczna | |
| SG11202113265PA (en) | Triple pharmaceutical composition for proteinaceous infection | |
| EP4034567A4 (en) | PHARMACEUTICAL COMPOSITIONS WITH POH DERIVATIVES | |
| GB202018068D0 (en) | Pharmaceutical composition | |
| GB202010340D0 (en) | Pharmaceutical composition | |
| EP3903782A4 (en) | PHARMACEUTICAL COMPOSITION | |
| EP3806838A4 (en) | PHARMACEUTICAL COMPOSITIONS COMPRISING POH DERIVATIVES | |
| HK40079778A (en) | Pharmaceutical compositions | |
| EP4066852A4 (en) | PHARMACEUTICAL COMPOSITION | |
| HK40078444A (en) | Pharmaceutical composition comprising selexipag | |
| HK40067652A (en) | Pharmaceutical composition comprising ensifentrine | |
| HK40059385A (en) | Pharmaceutical composition | |
| HK40065721A (en) | Pharmaceutical formulations | |
| HK40077614A (en) | Pharmaceutical compounds | |
| HK40068353A (en) | Cannabidiol pharmaceutical compositions | |
| HK40076183A (en) | Pharmaceutical compounds | |
| GB202020504D0 (en) | Pharmaceutical composition | |
| HK40068990A (en) | Pharmaceutical compounds | |
| GB202019237D0 (en) | Pharmaceutical composition |